Eone Diagnomics Genome Center
Incheon, Inch'on-jikhalsi, South Korea
About Eone Diagnomics Genome Center
Eone Diagnomics Genome Center Stepping Forward to Be a Global Leader in Genomic Diagnostics. It has been created by Eone Life Science Institute (ELSI) and DIAGNOMICS as a joint venture in an effort to find new solutions for diseases that afflict mankind. EDGC provides professional genomic analysis services for genetic diseases and cancer-centric medicines based on its know-how of genome interpretation and analysis and is creating new prospects for prenatal tests in order to develop unique non-invasive prenatal tests using next-generation sequencing technology. EDGC and Diagnomics currently possess a genomic analysis-driven digital genome fingerprinting technology and derived bioinformatics & NGS technologies focused on the research and development of monitoring techniques for cancer, non-invasive prenatal test, immune-rejection in organ transplantation and HAI through genomic analysis technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Funding stage: Private Equity
- Last round: Private Equity (Dec 2017)
- Website: edgc.com
- Phone: 82-32-713-2140
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/eone-diagnomics-genome-center-2473014 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.